Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - salmeterol xinafoate, quantity: 72.5 microgram/actuation (equivalent: salmeterol, qty 50 microgram/actuation); fluticasone propionate, quantity: 500 microgram/actuation - inhalation, powder for - excipient ingredients: lactose monohydrate - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include: patients on effective maintenance doses of long-acting beta2-agonists and inhaled corticosteroids. patients who are symptomatic on current inhaled corticosteroid therapy. initiation of maintenance therapy in those patients with moderate persistent asthma not adequately controlled on as needed reliever medication, and who have moderate/severe airway limitation and daily symptoms requiring reliever medication every day (see clinical trials). for the symptomatic treatment of patients with severe copd (fev1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. seretide is not indicated for the initiation of bronchodilator therapy in copd.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 250 microgram/actuation; salmeterol xinafoate, quantity: 72.5 microgram/actuation (equivalent: salmeterol, qty 50 microgram/actuation) - inhalation, powder for - excipient ingredients: lactose monohydrate - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include: patients on effective maintenance doses of long-acting beta2-agonists and inhaled corticosteroids. patients who are symptomatic on current inhaled corticosteroid therapy. initiation of maintenance therapy in those patients with moderate persistent asthma not adequately controlled on as needed reliever medication, and who have moderate/severe airway limitation and daily symptoms requiring reliever medication every day (see clinical trials). for the symptomatic treatment of patients with severe copd (fev1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. seretide is not indicated for the initiation of bronchodilator therapy in copd.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - salmeterol xinafoate, quantity: 72.5 microgram/actuation (equivalent: salmeterol, qty 50 microgram/actuation); fluticasone propionate, quantity: 100 microgram/actuation - inhalation, powder for - excipient ingredients: lactose monohydrate - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include: patients on effective maintenance doses of long-acting beta2-agonists and inhaled corticosteroids. patients who are symptomatic on current inhaled corticosteroid therapy. initiation of maintenance therapy in those patients with moderate persistent asthma not adequately controlled on as needed reliever medication, and who have moderate/severe airway limitation and daily symptoms requiring reliever medication every day (see clinical trials). for the symptomatic treatment of patients with severe copd (fev1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. seretide is not indicated for the initiation of bronchodilator therapy in copd.

United States - English - NLM (National Library of Medicine)

aurobindo pharma limited - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 250 mg - levofloxacin tablets are indicated in adult patients for the treatment of nosocomial pneumonia due to methicillin-susceptible staphylococcus aureus, pseudomonas aeruginosa, serratia marcescens, escherichia coli, klebsiella pneumoniae, haemophilus influenzae, or streptococcus pneumoniae . adjunctive therapy should be used as clinically indicated. where pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see clinical studies (14.1)] . levofloxacin tablets are indicated in adult patients for the treatment of community-acquired pneumonia due to methicillin-susceptible staphylococcus aureus, streptococcus pneumoniae (including multi-drug-resistant streptococcus pneumoniae [mdrsp]), haemophilus influenzae, haemophilus parainfluenzae, klebsiella pneumoniae, moraxella catarrhalis, chlamydophila pneumoniae, legionella pneumophila, or mycoplasma pneumoniae [see  dosage and administration (2.1) and clinical studies (14.2 )]. mdrsp i

United States - English - NLM (National Library of Medicine)

upsher-smith laboratories, llc - warfarin sodium (unii: 6153cwm0cl) (warfarin - unii:5q7zvv76ei) - warfarin sodium 1 mg - jantoven® is indicated for: - prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism (pe). - prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation (af) and/or cardiac valve replacement. - reduction in the risk of death, recurrent myocardial infarction (mi), and thromboembolic events such as stroke or systemic embolization after myocardial infarction. limitations of use warfarin sodium has no direct effect on an established thrombus, nor does it reverse ischemic tissue damage. once a thrombus has occurred, however, the goals of anticoagulant treatment are to prevent further extension of the formed clot and to prevent secondary thromboembolic complications that may result in serious and possibly fatal sequelae. jantoven is contraindicated in: - pregnancy jantoven is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see warnings and precautions (5.7) and

United States - English - NLM (National Library of Medicine)

aurobindo pharma limited - didanosine (unii: k3gdh6oh08) (didanosine - unii:k3gdh6oh08) - didanosine 125 mg - didanosine delayed-release capsules, also known as ddi, in combination with other antiretroviral agents are indicated for the treatment of human immunodeficiency virus (hiv)-1 infection [see clinical studies (14) ] . didanosine delayed-release capsules are contraindicated when coadministered with the following medications: - stavudine- potential for serious and/or life-threatening events, notably pancreatitis, lactic acidosis, hepatotoxicity, and peripheral neuropathy [see warnings and precautions (5.1, 5.2, 5.3, 5.5)] . - allopurinol- systemic exposures of didanosine are increased, which may increase didanosine-associated toxicity [see clinical pharmacology (12.3) ]. - ribavirin- exposures of the active metabolite of didanosine (dideoxyadenosine 5′-triphosphate) are increased. fatal hepatic failure, as well as peripheral neuropathy, pancreatitis, and symptomatic hyperlactatemia/lactic acidosis have been reported in patients receiving both didanosine and ribavirin. pregnancy exposure registry there is a preg

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

pharma house pharmaceuticals india - 50's (10's blister x 5) - tablet - 50 mg/tablet - endocrine system-thyroid , antithyroid

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

50's (10's blister x 5) -

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - goserelin acetate 11.34mg equivalent to 10.8 mg goserelin;   - injection (depot) - 10.8 mg - active: goserelin acetate 11.34mg equivalent to 10.8 mg goserelin   excipient: polyglactin - zoladex 10.8 mg is indicated for the management of: 1. prostate cancer suitable for hormonal manipulation.

United States - English - NLM (National Library of Medicine)

sandoz inc - fluphenazine hydrochloride (unii: zou145w1xl) (fluphenazine - unii:s79426a41z) - fluphenazine hydrochloride 1 mg - fluphenazine hcl is indicated in the management of manifestations of psychotic disorders. fluphenazine hcl has not been shown effective in the management of behavioral complications in patients with mental retardation. phenothiazines are contraindicated in patients with suspected or established subcortical brain damage, in patients receiving large doses of hypnotics, and in comatose or severely depressed states. the presence of blood dyscrasia or liver damage precludes the use of fluphenazine hydrochloride. fluphenazine hcl is contraindicated in patients who have shown hypersensitivity to fluphenazine; cross-sensitivity to phenothiazine derivatives may occur.